canakinumab and pharmaceutically acceptable derivatives (ilaris u00ae)

• 收藏
• 分享

专利权人:

Novartis AG

发明人:

GRAM Hermann,DI PADOVA Franco, E.

申请号：

LU91624

公开号：

LU91624I9

申请日:

2009.11.25

申请国别(地区):

LU

年份:

2018

代理人:

摘要：

An IL-1&bgr； binding molecule, in particular an antibody to human IL-1&bgr；, especially a human antibody to human IL-1&bgr； is provided, wherein the CDRs of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-1 mediated disease or disorder, e.g. osteoarthritis, osteoporosis and other inflammatory arthritides.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/